Lodestar

GKOS

GLAUKOS Corp
NYSESurgical & Medical Instruments & ApparatusLatest fiscal year ended Dec 31, 2025

GLAUKOS Corp reported revenue of $507.44M in its most recent fiscal year, up 32.3% on the year before. It kept -37.0% of that as net income, and generated -$22.45M of free cash flow. Figures below are compared against other companies classified under Surgical & Medical Instruments & Apparatus.

Grades vs. industry

Growth
B68/100
Ranked against 71 peers using 3 metrics.
Profitability
D35/100
Ranked against 80 peers using 7 metrics.
Financial health
C49/100
Ranked against 64 peers using 3 metrics.

Growth

MetricCompanyIndustry medianRank
Revenue growth (YoY)
Latest fiscal year revenue vs. the year before.
32.3%13.9%19 / 90
Revenue growth (3y)
Annualized revenue growth over three fiscal years.
21.5%14.1%27 / 80
Revenue growth (5y)
Annualized revenue growth over five fiscal years.
17.7%15.3%30 / 71
EPS growth (YoY)
Diluted EPS vs. the prior fiscal year.
Not reported15.4%—
EPS growth (3y)
Annualized diluted EPS growth over three fiscal years.
Not reported17.1%—
EPS growth (5y)
Annualized diluted EPS growth over five fiscal years.
Not reported12.2%—
Free cash flow growth (YoY)
Operating cash flow less capital expenditure, vs. prior year.
Not reported2.5%—
Free cash flow growth (3y)
Annualized free cash flow growth over three fiscal years.
Not reported28.1%—

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Profitability

MetricCompanyIndustry medianRank
Gross margin
Gross profit as a share of revenue. Often unreported.
55.7%62.4%58 / 88
Operating margin
Operating income as a share of revenue.
-39.3%-10.3%62 / 88
Net margin
Net income as a share of revenue.
-37.0%-11.9%63 / 90
Free cash flow margin
Free cash flow as a share of revenue.
-4.4%-1.1%46 / 83
Return on equity
Net income divided by shareholder equity.
-28.6%-16.0%51 / 83
Return on assets
Net income divided by total assets.
-21.0%-10.1%61 / 90
Return on invested capital
After-tax operating profit over debt plus equity less cash.
-27.9%-13.1%53 / 80

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Financial health

MetricCompanyIndustry medianRank
Debt to equity
Total debt divided by shareholder equity.
Not reported0.47x—
Current ratio
Current assets over current liabilities.
4.69x2.99x28 / 90
Quick ratio
Current assets excluding inventory, over current liabilities.
4.06x2.40x28 / 90
Interest coverage
Operating income divided by interest expense.
-43.06x-1.99x60 / 64
Net debt to EBITDA
Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed.
Not reported0.65x—

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Insider activity

Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 34 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.

DateInsiderTransactionSharesPriceValue
Oct 5, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale888$163.93$145.6K
Oct 5, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale327$164.78$53.9K
Oct 5, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale312$165.60$51.7K
Sep 25, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale1,083$154.88$167.7K
Sep 25, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale229$154.24$35.3K
Sep 25, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale167$151.70$25.3K
Sep 25, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale136$152.71$20.8K
Sep 16, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale460$167.32$77.0K
Sep 16, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale345$164.60$56.8K
Sep 16, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale234$170.95$40.0K
Sep 16, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale191$166.20$31.7K
Sep 16, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale120$168.38$20.2K
Sep 16, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale103$163.20$16.8K
Sep 16, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale4$172.00$688.00
Aug 28, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale7,643$180.25$1.38M
Aug 28, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale6,091$181.19$1.10M
Aug 28, 2026
Navratil Tomas
CHIEF DEVELOPMENT OFFICER
Open-market sale10$182.50$1.8K
Aug 19, 2026
Kliman Gilbert H
Director
Open-market sale2,500$190.00$475.0K
Aug 19, 2026
Kliman Gilbert H
Director
Option exercise2,500$25.77$64.4K
Aug 19, 2026
Kliman Gilbert H
Director
Option exercise(derivative)2,500$0.00$0.00
Aug 11, 2026
Gilliam Joseph E
PRESIDENT & COO
Open-market sale32,037$180.49$5.78M
Aug 11, 2026
Gilliam Joseph E
PRESIDENT & COO
Open-market sale27,963$178.89$5.00M
Aug 11, 2026
Gilliam Joseph E
PRESIDENT & COO
Option exercise20,000$55.18$1.10M
Aug 11, 2026
Gilliam Joseph E
PRESIDENT & COO
Option exercise20,000$55.18$1.10M
Aug 11, 2026
Gilliam Joseph E
PRESIDENT & COO
Option exercise10,000$48.46$484.6K

A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.

Annual financials

Fiscal year2025202420232022202120202019201820172016
Revenue$507.44M$383.48M$314.71M$282.86M$294.01M$224.96M$236.98M$181.28M$159.25M$114.40M
Gross profit$282.76M$289.45M$239.14M$213.88M$227.38M$133.24M$198.40M$156.20M$138.20M$98.22M
Operating income-$199.60M-$122.37M-$128.70M-$82.31M-$32.87M-$123.55M-$50.29M-$13.00M-$2.28M$4.24M
Net income-$187.69M-$146.37M-$134.66M-$99.19M-$49.59M-$120.35M$15.42M-$12.95M-$92.0K$4.52M
EPS (diluted)-$3.28-$2.77-$2.78-$2.09-$1.07-$2.70$0.37-$0.37$0.00$0.12
Operating cash flow-$14.79M-$61.32M-$57.76M-$33.08M$24.71M-$22.99M-$369.0K$18.86M$26.09M$12.31M
Capital expenditure$7.67M$6.30M$20.25M$30.27M$47.78M$6.93M$4.72M$10.31M$6.31M$6.28M
Free cash flow-$22.45M-$67.62M-$78.01M-$63.35M-$23.08M-$29.92M-$5.09M$8.55M$19.78M$6.03M
Total assets$893.49M$974.76M$940.41M$1.00B$1.05B$1.01B$818.40M$206.97M$165.84M$134.37M
Shareholder equity$656.15M$766.93M$461.77M$530.00M$587.15M$667.45M$673.27M$173.86M$138.20M$117.27M
Cash$90.81M$169.63M$93.47M$119.53M$100.71M$96.60M$62.43M$29.82M$24.51M$6.49M

A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.

Source

Figures come from GLAUKOS Corp’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Feb 23, 2026. View filings on EDGAR.

Not financial advice. This page presents figures reported to the SEC and compares them with other companies sharing an industry classification. It is not a recommendation to buy or sell anything, and the grades cannot capture everything that matters about a business. Industry classifications are coarse, filings are self-reported, and some figures are missing or understated where companies tag them in ways this site does not match. Do your own research.